Morrissey & anor v Health Service Executive & ors

Factual and Procedural Background

The plaintiffs, a married couple with one child, initiated a negligence claim against three defendants relating to the alleged failure to correctly report two cervical smear tests conducted in 2009 and 2012. The first test was performed by the second defendant in the United States, and the second by the third defendant in Ireland. The plaintiffs also alleged breaches of Constitutional and European Convention Rights and sought exemplary damages. The first defendant, a state health service entity, had contracted out cervical screening services to multinational laboratories, including the second and third defendants, under specific quality assurance guidelines. The first plaintiff was diagnosed with cervical cancer in 2014 after two prior negative smear tests, which were later audited and found to have been inaccurately reported. The audit results were not disclosed to the plaintiffs until 2018, following public controversy. The plaintiffs claim that earlier correct reporting and follow-up would have prevented the cancer and its recurrence, resulting in a less severe prognosis and less invasive treatment. The defendants deny liability and causation, asserting that the cancer was not present or detectable at the time of the tests, and dispute the extent of any negligence. The case involved detailed expert evidence on the standards of care, adequacy of samples, and the interpretation of cytology slides. Procedurally, the case commenced in mid-2018, with adjournments and expansions of the pleadings, including late allegations concerning post-treatment follow-up care and imaging.

Legal Issues Presented

1. The applicable standard of care for the cytology screening and reporting.
2. Whether the defendants were negligent or in breach of duty regarding the August 2009 smear test.
3. Whether the defendants were negligent or in breach of duty regarding the August 2012 smear test.
4. If negligence is established, what are the consequences for the plaintiffs?
5. Whether the plaintiffs have claims for breach of Constitutional and/or European Convention Rights.
6. Whether the first defendant was negligent in failing to advise the first plaintiff to undergo additional imaging after initial cancer treatment in 2014 and whether any additional injuries resulted from the delayed disclosure of audit results.
7. Whether the first plaintiff is entitled to damages for the admitted breach of the first defendant in failing to disclose audit results.
8. Assessment of damages including entitlement of the second plaintiff, future care, loss of earnings, exemplary damages, and quantum of damages.
9. The liability of the various defendants.

Arguments of the Parties

The opinion does not contain a detailed account of the parties' legal arguments.

Table of Precedents Cited

Court's Reasoning and Analysis

The court undertook a detailed and methodical analysis of the evidence, applying established legal principles and precedents. The primary legal standard for negligence was the Dunne test, which requires proof that the defendant’s conduct was such that no other competent professional would have acted similarly with ordinary care. The court distinguished between factual findings—what was actually present on the smear slides—and legal conclusions regarding negligence.

The analysis emphasized the importance of the "absolute confidence" standard for screeners when classifying slides as negative. The court rejected the American Society of Cytopathology guidelines as setting the legal standard, noting their origin in litigation defense and their incompatibility with Irish law.

Regarding the 2009 smear test, the court found, based on expert evidence and slide photographs, that abnormal glandular cells were present and should have been identified. It was held that a reasonably competent screener should not have failed to detect these abnormalities and that treating the slide as negative was negligent.

For the 2012 smear test, although abnormal cells were present, the sample was scanty and the abnormalities were less distinct. The court found that a reasonably competent screener could have failed to see the abnormality and could have treated the slide as negative without breaching the standard of care. However, the court found negligence in failing to properly assess the adequacy of the sample according to the Bethesda system, which would have required a retest.

The court rejected the defendants’ arguments that the cancer developed rapidly or was not present at the time of the tests, accepting expert clinical evidence that the cancer developed over the usual ten-year period. Consequently, the failure to detect and act upon abnormal results led to the plaintiff’s cancer diagnosis and subsequent injuries.

The court also addressed claims of breach of constitutional and Convention rights, finding these claims overlapped with tort claims and did not require separate analysis.

Regarding post-treatment follow-up, the court found no breach of duty in failing to require routine imaging scans absent symptoms, and rejected the plaintiff’s claim that delayed disclosure of audit results caused additional personal injury.

The first defendant admitted breach of duty in failing to disclose audit results, but the court held that this caused no compensable injury beyond nominal damages.

The court carefully considered the second plaintiff’s claim for psychiatric injury and physical illness resulting from stress, concluding that while a duty of care existed for loss of consortium damages, the personal injury claims failed on public policy and foreseeability grounds.

On exemplary damages, the court found no egregious or wilful misconduct by any defendant warranting punitive awards, noting that negligence was due to inadvertence and systemic issues rather than deliberate wrongdoing.

In assessing damages, the court applied relevant precedents and actuarial evidence. It allowed substantial general and special damages for the first plaintiff’s catastrophic injury and limited life expectancy, applied the statutory cap on general damages, and awarded damages for loss of consortium, loss of earnings, and future care to the second plaintiff. The court also addressed the issue of indemnity and contribution among the defendants, holding all liable as concurrent wrongdoers, with contractual indemnities in place.

Holding and Implications

The court rendered the following decisions:

• The defendants were negligent and in breach of duty in relation to the August 2009 smear test.
• The defendants were negligent in failing to properly assess the adequacy of the 2012 smear sample, constituting a breach of duty, but not negligent in the interpretation of abnormal cells on that slide.
• The plaintiffs' claims for breach of Constitutional and/or European Convention Rights were not sustained beyond the tort claims.
• The first defendant was not negligent in post-treatment follow-up imaging, nor did the delayed disclosure of audit results cause additional compensable injury.
• The first defendant admitted breach of duty in failing to disclose audit results and the first plaintiff was awarded nominal damages for this breach.
• The second plaintiff is entitled to damages for loss of consortium but not for personal injuries claimed due to stress and colitis.
• The plaintiffs are not entitled to exemplary damages; the conduct of the defendants, while negligent, was not egregious or wilful.
• The court awarded damages totaling €2,162,508: approximately €757,508 to the first plaintiff and €1,405,000 to the second plaintiff.
• All defendants are concurrent wrongdoers and jointly and severally liable for damages except for the €10,000 awarded solely against the first defendant for nondisclosure of audit results.
• The first defendant is entitled to indemnity or contribution from the second and third defendants for all damages except the €10,000 nominal damages.

The decision directly affects the parties by affirming liability and awarding substantial damages for negligence in cervical smear testing and related failures. It clarifies the applicable standards of care in cytology screening, rejects certain American professional guidelines as legal standards, and confirms the scope of liability and indemnity among contracted parties. No new legal precedent beyond the application of established principles was set, but the judgment provides detailed guidance on the assessment of negligence in medical screening and the handling of audit disclosures.